Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Pilot Study of Sorafenib for Myelodysplastic Syndrome

Arati Rao, MD, David A. Rizzieri, MD, Eduardo Vanegas, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Donna Adams, RN, Julie Warzecho, RN, Carlos Decastro, MD

Blood (2012) 120 (21): 4948.

https://doi.org/10.1182/blood.V120.21.4948.4948

Published: 2012

Journal Articles

Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS

Arati Rao, MD, Ghazi Khan, David A. Rizzieri, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Anne W Beaven, MD, Donna Adams, RN, Julie Warzecho, RN, Carlos Decastro, MD

Blood (2012) 120 (21): 4935.

https://doi.org/10.1182/blood.V120.21.4935.4935

Published: 2012

Journal Articles

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Danielle M. Brander, MD, Anne W Beaven, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Cristina Gasparetto, MD, Thomas C. Shea, MD, Carlos deCastro, Joseph O. Moore, MD, David A. Rizzieri, MD

Blood (2012) 120 (21): 1626.

https://doi.org/10.1182/blood.V120.21.1626.1626

Published: 2012

Journal Articles

High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma

Anne W Beaven, MD, David A. Rizzieri, MD, Zachary Powell, Zhiguo Li, PhD, Peggy Alton, RN, Julie Warzecho, RN, Louis F. Diehl, MD, Joseph O. Moore, MD, Carlos Manuel de Castro, III, MD, Jon P. Gockerman, MD

Blood (2011) 118 (21): 2681.

https://doi.org/10.1182/blood.V118.21.2681.2681

Published: 2011

Journal Articles

Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia,

Tod A. Morris, MD, David A. Rizzieri, MD, Carlos M de Castro, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Anand S. Lagoo, MD, PhD, Joseph O. Moore, MD, Arati V Rao, MD

Blood (2011) 118 (21): 3590.

https://doi.org/10.1182/blood.V118.21.3590.3590

Published: 2011

Journal Articles

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

Arati V Rao, MD, David A. Rizzieri, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Mitchell E. Horwitz, MD, Joseph O. Moore, MD, Natalie Sacarakis, Carlos Manuel de Castro, III, MD

Blood (2011) 118 (21): 5021.

https://doi.org/10.1182/blood.V118.21.5021.5021

Published: 2011

Journal Articles

A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS Int-2 or High) Myelodysplastic Syndrome

Carlos Manuel de Castro, III, MD, Donna Adams, RN, Arati V Rao, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Anne W Beaven, MD, Julie Warzecho, RN, David A. Rizzieri, MD

Blood (2011) 118 (21): 5029.

https://doi.org/10.1182/blood.V118.21.5029.5029

Published: 2011

Journal Articles

Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells

J. Brice Weinberg, MD, David J. DiLillo, PhD, Yohei Iwata, PhD, Takashi Matushita, PhD, Karen M. Matta, BS, Guglielmo M. Venturi, PhD, Giandomenico Russo, MD, PhD, Youwei Chen, MD, Jon P. Gockerman, MD, Joseph O. Moore, MD, Louis F. Diehl, MD, Alicia D. Volkheimer, MS, Daphne R. Friedman, M.D., Mark C Lanasa, MD, PhD, Russell P. Hall, MD, Thomas J. Tedder, PhD

Blood (2011) 118 (21): 286.

https://doi.org/10.1182/blood.V118.21.286.286

Published: 2011

Journal Articles

A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients with Relapsed/Refractory Mulitple Myeloma

Lauren Held, Jon P. Gockerman, MD, Louis F. Diehl, MD, Carlos Manuel de Castro, III, MD, Joseph O. Moore, MD, David A. Rizzieri, MD, Gwynn D. Long, MD, Mitchell E. Horwitz, MD, Nelson J. Chao, MD, Cristina Gasparetto, MD

Blood (2011) 118 (21): 5129.

https://doi.org/10.1182/blood.V118.21.5129.5129

Published: 2011

Journal Articles

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

Dale J. Christensen, Youwei Chen, Jessica Oddo, Karen M. Matta, Jessica Neil, Evan D. Davis, Alicia D. Volkheimer, Mark C. Lanasa, Daphne R. Friedman, Barbara K. Goodman, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Michael P. Vitek, J. Brice Weinberg

Blood (2011) 118 (15): 4150–4158.

https://doi.org/10.1182/blood-2011-04-351072

Published: 2011

Includes: Supplemental data

Journal Articles

Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Daphne R. Friedman, MD, Patricia H. Davis, RN, BSN, OCN, Mark C. Lanasa, MD, PhD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Taylor Nelson, BS, Karen M. Bond, BS, Ning Jiang, MD, Evan D. Davis, BS, Sallie D. Allgood, MS, Youwei Chen, MD, Peter Sportelli, J. Brice Weinberg, MD

Blood (2010) 116 (21): 1842.

https://doi.org/10.1182/blood.V116.21.1842.1842

Published: 2010

Journal Articles

Targeting Destruction of Mcl-1 by Activation of Protein Phosphatase 2A In CLL and B-Cell Lymphomas

Dale J. Christensen, PhD, Jessica Oddo, B.S., Karen Bond, Alicia Volkheimer, M.S., Youwei Chen, MD, Evan Davis, BS, Jon P. Gockerman, MD, Louis F. Diehl, MD, Carlos de Castro, III, MD, Joseph O. Moore, MD, Michael P Vitek, PhD, J. Brice Weinberg, MD

Blood (2010) 116 (21): 4190.

https://doi.org/10.1182/blood.V116.21.4190.4190

Published: 2010

Journal Articles

Family-Associated Monoclonal B Lymphocytosis Shows Differences From CLL That Suggest An Indolent Biology.

Mark C Lanasa, MD, PhD, Sallie D Allgood, MS, Susan L Slager, PhD, Nicola J Camp, PhD, Neil E. Kay, MD, Logan G Spector, PhD, Laura Z. Rassenti, PhD, Curtis A. Hanson, MD, Jon P Gockerman, MD, Barbara K Goodman, PhD, Sara S Strom, PhD, Timothy G Call, MD, James R Cerhan, MD, PhD, Jose Leis, MD, Gerald Marti, MD, PhD, Lynn Goldin, PhD, J. Brice Weinberg, Neil E Caporaso, MD

Blood (2009) 114 (22): 1241.

https://doi.org/10.1182/blood.V114.22.1241.1241

Published: 2009

Journal Articles

The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.

Dale J. Christensen, PhD, Karen M. Bond, BS, Alicia D. Volkheimer, MS, Jessica Oddo, BS, Youwei Chen, MD, Jon P. Gockerman, MD, Joseph O. Moore, MD, Louis F. Diehl, MD, Carlos M. de Castro, MD, Michael P. Vitek, PhD, J. Brice Weinberg, MD

Blood (2009) 114 (22): 802.

https://doi.org/10.1182/blood.V114.22.802.802

Published: 2009

Journal Articles

Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.

Cristina Gasparetto, MD, Jon P Gockerman, Louis F Diehl, MD, Carlos de Castro, III, MD, Joseph O Moore, Gwynn D Long, Mitchell Horwitz, MD, John Chute, MD, Keith M Sullivan, MD, Rachel Neuwirth, Patricia H Davis, Linda M. Sutton, Russell D Anderson, Nelson Chao, David A. Rizzieri, MD

Blood (2008) 112 (11): 3325.

https://doi.org/10.1182/blood.V112.11.3325.3325

Published: 2008

Journal Articles

Apolipoprotein E-Mimetic Therapeutic Peptides Mediate CLL Cell Cytotoxicity

Blood (2008) 112 (11): 359.

https://doi.org/10.1182/blood.V112.11.359.359

Published: 2008

Journal Articles

Family-Associated Monoclonal B Lymphocytosis Is Commonly Oligoclonal and Expresses Markers Associated with Adverse Risk in CLL

Mark C Lanasa, MD, PhD, Sallie D Allgood, MS, Susan L. Slager, PhD, Nicola Camp, PhD, Logan Spector, PhD, Laura Rassenti, PhD, Neil E. Kay, Jon P Gockerman, MD, Alicia Volkheimer, MS, Barbara K Goodman, PhD, Sara Strom, PhD, Timothy Call, MD, James Cerhan, MD, PhD, Jose F Leis, MD, PhD, Lynn Goldin, PhD, Gerald Marti, MD, PhD, J Brice Weinberg, MD, Neil Caporaso, MD, Marc C. Levesque, MD, PhD

Blood (2008) 112 (11): 3144.

https://doi.org/10.1182/blood.V112.11.3144.3144

Published: 2008

Journal Articles

Monoclonal B Cell Lymphocytosis Exhibits Biologic Diversity Similar to Chronic Lymphocytic Leukemia.

Mark C. Lanasa, MD, PhD, Sallie D. Allgood, MS, Barbara K. Goodman, PhD, John F. Whitesides, PhD, Jon P. Gockerman, MD, Joseph O. Moore, MD, J. Brice Weinberg, MD, Marc C. Levesque, MD, PhD

Blood (2007) 110 (11): 3084.

https://doi.org/10.1182/blood.V110.11.3084.3084

Published: 2007

Journal Articles

Functional and Numerical T Cell Abnormalities in Chronic Lymphocytic Leukemia.

Mark C. Lanasa, MD, PhD, Marc C. Levesque, MD,PhD, Sallie D. Allgood, MS, Jon P. Gockerman, MD, Karen Bond, BA, J. Brice Weinberg, MD

Blood (2007) 110 (11): 3085.

https://doi.org/10.1182/blood.V110.11.3085.3085

Published: 2007

Journal Articles

Monoclonal B Cell Lymphocytosis as a Marker of Inherited Predisposition to Chronic Lymphocytic Leukemia.

Mark C. Lanasa, MD, PhD, Marc C. Levesque, MD,PhD, Jon P. Gockerman, MD, Sallie D. Allgood, MS, Joseph O. Moore, MD, John F. Whitesides, PhD, J. Brice Weinberg, MD

Blood (2007) 110 (11): 3090.

https://doi.org/10.1182/blood.V110.11.3090.3090

Published: 2007

NARROW

Pilot Study of Sorafenib for Myelodysplastic Syndrome

Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma

Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia,

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS Int-2 or High) Myelodysplastic Syndrome

Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells

A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients with Relapsed/Refractory Mulitple Myeloma

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Targeting Destruction of Mcl-1 by Activation of Protein Phosphatase 2A In CLL and B-Cell Lymphomas

Family-Associated Monoclonal B Lymphocytosis Shows Differences From CLL That Suggest An Indolent Biology.

The SET Oncogene, a Potent PP2A Inhibitor, Is Elevated in CLL and Antagonism of SET Induces Apoptosis.

Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.

Apolipoprotein E-Mimetic Therapeutic Peptides Mediate CLL Cell Cytotoxicity

Family-Associated Monoclonal B Lymphocytosis Is Commonly Oligoclonal and Expresses Markers Associated with Adverse Risk in CLL

Monoclonal B Cell Lymphocytosis Exhibits Biologic Diversity Similar to Chronic Lymphocytic Leukemia.

Functional and Numerical T Cell Abnormalities in Chronic Lymphocytic Leukemia.

Monoclonal B Cell Lymphocytosis as a Marker of Inherited Predisposition to Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only